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Abstract
The complement cascade includes heat-labile proteins and care is required when handling serum in order to preserve its
functional integrity. We have previously used a whole human serum bactericidal assay to show that antibody and an intact
complement system are required in blood for killing of invasive isolates of Salmonella. The aim of the present study was to
evaluate the conditions under which human serum can be stored and manipulated while maintaining complement
integrity. Serum bactericidal activity against Salmonella was maintained for a minimum of 35 days when stored at 4uC, eight
days at 22uC and 54 hours at 37uC. Up to three freeze-thaw cycles had no effect on the persistence of bactericidal activity
and hemolytic complement assays confirmed no effect on complement function. Delay in the separation of serum for up to
four days from clotted blood stored at 22uC did not affect bactericidal activity. Dilution of serum resulted in an increased
rate of loss of bactericidal activity and so serum should be stored undiluted. These findings indicate that the current
guidelines concerning manipulation and storage of human serum to preserve complement integrity and function leave
a large margin for safety with regards to bactericidal activity against Salmonella. The study provides a scheme for
determining the requirements for serum handling in relation to functional activity of complement in other systems.
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Introduction
Complement comprises a set of plasma proteins that facilitate
the killing of pathogens by antibody [1,2]. This involves a number
of mechanisms including cell-independent bactericidal activity
with formation of membrane attack complex, and opsonization for
uptake and killing by phagocytic cells. We have previously studied
the ability of whole human serum from Africans to effect cell-
independent and facilitate cell-mediated killing of African invasive
isolates of nontyphoidal Salmonella. We have found that these
mechanisms of bacterial killing require both antibody and
complement [3,4].
It has long been known that complement activity is heat-labile
[5,6] and is destroyed by exposure to 56uC for 30 minutes, while
antibody is relatively resistant to such treatment [7]. Therefore,
careful processing and manipulation of blood and serum for use in
functional complement assays is required to avoid false-negative
results [8]. Thus it is advocated that serum is promptly separated
from clotted blood and stored at 280uC in aliquots to avoid
freeze-thaw cycles. It is also normal practice for serum aliquots to
only be used on the day they are thawed, and that experiments
involving complement are carried out on ice or under refrigerated
conditions at 4uC.
We have been able to uncover only limited objective data about
the stability of the human complement components required to
induce cell free and phagocyte-mediated lysis of bacteria in vitro.
Hemolytic assays are normally used for such investigations of
complement stability [6] and these normally focus on animal
serum, in particularly guinea pig serum [6]. There are several
studies showing functional differences in complement between
species including humans [9].
We conducted the current study to determine acceptable
conditions for manipulation of human serum that would not be
detrimental to its ability to kill Salmonella in our cell-free
bactericidal assays. In this study, we explored the longevity of
bactericidal activity at different temperatures, effect of freeze-thaw
cycles and effect of delayed separation of serum from blood. We
were able to determine the conditions for preservation of serum
complement activity for use in our assay system. The study also
serves to provide a scheme for assessing serum handling in order to
maintain complement function for other in vitro functional assay
systems.
Materials and Methods
Ethical Approval
Ethical approval for the use of serum samples in this study was
granted by the Life and Health Sciences Ethical Review
Committee of the University of Birmingham. Informed written
consent was obtained from all participants.
Serum
Blood was venesected from four healthy adults (two male, two
female) and left to clot at 4uC for 8 hours or at 22uC for from zero
PLOS ONE | www.plosone.org 1 November 2012 | Volume 7 | Issue 11 | e49147
Figure 1. Percentage of human serum stored at 22uC required to kill S. Typhimurium D23580 and anti-S. Typhimurium antibody
levels in study sera. Killing of bacteria by different percentages of freshly thawed serum from A. subject 1 and B. subject 2 at 45, 90 and 180
minutes in serum bactericidal assay using 106 cfu/ml S. Typhimurium D23580:10% (red circles), 20% (green squares), 30% (blue triangles), 40% (purple
diamonds) and 50% (orange inverted triangles) serum diluted with PBS, 100% PBS (black crosses), 100% fresh serum (pink vertical crosses) and 100%
heat-inactivated serum (blue circle and dashed lines). Initial concentration of bacteria 106 cfu/ml with numbers of viable bacteria plotted against
duration of assay. Killing of bacteria by different percentages of serum from C. subject 1 and D. subject 2 at 180 minutes following storage at 22uC.
Change in viable count (cfu/ml) plotted against duration of time serum stored at 22uC. E. Levels of anti-S. Typhimurium D23580 IgG, IgA and IgM
antibodies in human sera used in study as assessed by flow cytometry. F. Killing of bacteria by fresh serum (solid lines) and heat-inactivated serum
(dashed lines) from subject 1 (red circles), 2 (green squares), 3 (blue triangles) and 4 (purple diamonds) at 45, 90 and 180 minutes.
doi:10.1371/journal.pone.0049147.g001
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to four days in the delayed serum-separation experiment. Serum
was separated by centrifugation at 4uC and frozen in aliquots at
280uC in sterile 8 ml polypropylene tubes (Sarstedt) or left at 4uC
or 22uC (in the delayed serum-separation experiment). When
required, frozen aliquots of serum were thawed on the bench at
22uC. Samples undergoing freeze-thaw cycles were immediately
refrozen at 280uC after reaching 22uC, and this was repeated
daily for up to three sequential days. Heat-inactivation of
complement was performed, when needed, by incubating serum
in a water bath at 56uC for 30 minutes.
Salmonella
Salmonella enterica serovar Typhimurium D23580, a well-charac-
terized invasive nontyphoidal Salmonella isolate from Malawi
[3,10], was used throughout the study. D23580 is sensitive to
antibody-dependent complement-mediated killing, undergoing
a one to three log10 reduction in bacterial numbers within three
hours of exposure to serum from healthy adults at 37uC [3].
Serum Bactericidal Assays
Serum bactericidal assays against Salmonella were as described
previously [3]. S. Typhimurium D23580 was grown at 37uC to
log-phase from an overnight culture in LB medium for two hours
and washed twice in PBS. 10 ml of washed bacteria resuspended in
PBS, without additional Mg2+ or Ca2+, was added to 90 ml of
serum in a microfuge tube to give a final concentration of 106 cfu/
ml in 90% serum, and incubated on a rocker plate at 37uC and
20 rpm. Viable numbers of Salmonellae were determined for the
washed bacterial inoculum and at 45, 90 and 180 minutes
exposure to serum by serial dilution in PBS followed by overnight
growth at 37uC on LB agar. Killing of Salmonellae was calculated by
subtracting the concentration of viable Salmonellae at the start of the
Figure 2. Effect of duration of storage of human serum at 4uC and freeze-thaw cycles on its ability to kill S. Typhimurium D23580.
Serum from four healthy adults (subjects 1–4 corresponding with panels A.–D.) following one (green squares), two (blue triangles), three (purple
diamonds) or no (red circles) freeze-thaw cycles was maintained at 4uC and examined at intervals for ability to kill in the serum bactericidal assay.
Normal killing designated as a reduction of 1.0 log10 cfu/ml viable bacteria. Numbers of viable Salmonellae after 180 minutes in the assay are plotted
against number of days serum kept at 4uC. Negative values show a decrease in viable bacteria compared with initial concentration. Classical (E.) and
alternative (F.) pathway hemolytic complement activity in sera from the four subjects (1– red circles, 2– green squares, 3– blue triangles, 4– purple
diamonds) stored at 4uC.
doi:10.1371/journal.pone.0049147.g002
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assay from the concentration of viable bacteria at each time point.
Serum bactericidal assays were performed with heat-inactivated
serum as a negative control. When required, for inhibition of
alternative pathway activity, polyclonal antibodies to Factor B
(ab8840, Abcam, Cambridge, UK) were added to the assay at
a final concentration of 0.92 mg/ml.
Anti-Salmonella Antibody Assays
Anti-S. Typhimurium D23580 IgG, IgA and IgM levels were
assessed by flow cytometry as previously described [3].
Figure 3. Effect of duration of storage of human serum at 22uC and 37uC on ability to kill S. Typhimurium D23580. Serum from the
same four adults as in Fig. 1 (1– red circles, 2– green squares, 3– blue triangles, 4– purple diamonds) was thawed and maintained at 22uC (A.) or 37uC
(B.) with serum bactericidal assays performed daily (for samples at 22uC) or six- to twelve-hourly (for samples at 37uC) using 106 cfu/ml. Viable bacteria
at 180 minutes in each serum bactericidal assay are plotted against duration of serum storage.
doi:10.1371/journal.pone.0049147.g003
Complement Activity Stability against Salmonella
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Complement Hemolytic Assays
Classical and alternative pathway hemolytic complement assays
were performed by radial immunodiffusion (Binding Site, UK)
according to the manufacturer’s instructions.
Statistics
The ANOVA test was used to compare groups of data within
the study using Prism version 5.02 (GraphPad Software,
California).
Results
The Percentage of Human Serum Required to Kill
Salmonella Increases Incrementally with Time
The ability of fresh adult human serum to kill Salmonella has
previously been shown to depend on specific IgG or IgM antibody
activating the classical complement pathway and the consequent
deposition of membrane attack complex on the bacterial surface
[3]. Serum samples from two healthy adults (subjects 1 and 2) were
studied for their ability to kill S. Typhimurium D23580 when
diluted in PBS. We confirmed the finding that, when first thawed,
serum concentrations of 20% or above are required to achieve
a 1.0 log10 cfu/ml kill of Salmonella (designated ‘normal’ killing) at
180 minutes in the serum bactericidal assay (Fig. 1A–B) [3].
Bacterial viability in 10% serum is similar to that of bacteria
cultured in complement-depleted serum.
When subsequently kept at 22uC, the ability of the diluted sera
to effect a normal kill decreased more rapidly than with whole
serum. The most dilute sera lost the ability to kill first: 20% sera
was unable to effect normal killing after one to three days, 30%
serum after three to four days, 40% serum after four to five days
and 50% after five to six days (Fig. 1C–D).
Human Sera used in the Study Contained Salmonella-
specific Antibody
In order to ascertain that all sera used in the study contained
antibody directed against Salmonella, we assessed the presence of
anti-Salmonella antibody targeting S. Typhimurium D23580 by
flow cytometry. Sera from all four healthy adult subjects contained
IgG, IgA and IgM classes of antibody capable of binding D23580
(Fig. 1E), indicating that these sera could activate complement
deposition on D23580 via the classical complement pathway [3].
To ensure that reductions in viable bacterial numbers in the serum
bactericidal assay were complement-dependent and did not result
from antibody alone, serum bactericidal assays were performed
following heat-inactivation of each serum. Bacterial numbers
increased relative to the starting concentration at each time point
in each serum (Fig. 1F).
Serum Bactericidal Activity Against Salmonella is
Retained for at least 35 days at 4uC
After these preliminary studies, further analysis of the decline in
bactericidal activity on storage were carried out using freshly-
frozen aliquots of serum from the four subjects and assessing the
bactericidal capacity of undiluted serum. Aliquots were subjected
to one, two, three or no freeze-thaw cycles and then maintained at
4uC with the serum bactericidal assays against S. Typhimurium
D23580, being repeated daily for the first week and then weekly.
During the first five weeks of the experiment (up to day 35), each
serum killed D23580 by approximately 2.0 log10 cfu/ml (Fig. 2A–
D). Thereafter, serum from subject 1 was unable to effect a 1.0
log10 cfu/ml kill (Fig. 2A), while serum from the remaining three
subjects maintained killing for 70 days (Fig. 1B–D) The serum
from subject 1 had no effect on the ability of other sera to kill
Salmonellae when combined with other sera in different proportions
in the serum bactericidal assay. There was no detectable difference
in the ability of serum that had undergone zero, one, two or three
freeze-thaw cycles to kill Salmonella D23580 (Fig. 2A–D).
A gradual reduction in classical pathway hemolytic complement
activity was observed with serum from each subject. Each serum
had over 1000 CH100 units/ml on day 0, less than 600 CH100
units/ml by day 28 to 42 and serum from 3 of the subjects had no
detectable activity on day 49, 63 or 84 (Fig. 2E). One serum (from
donor 4) still had detectable classical pathway activity at the end of
the experiment (day 91). Alternative pathway hemolytic comple-
ment activity was maintained at over 90% normal activity for 42
days in all sera, fell to less than 50% by day 77 and no activity was
detectable at 84 or 91 days (Fig. 2F).
Serum has Reduced Longevity of Bactericidal Activity
Against Salmonella when Stored at 22uC and 37uC
To investigate the effect of increasing the temperature at which
serum is stored on its bactericidal activity against S. Typhimurium,
the above experiment was repeated with serum from the same four
subjects maintained at either 22uC (Fig. 3A) or 37uC (Fig. 3B) post-
thawing. Sera kept at 22uC could effect a 2.0 to 3.0 log10 kill for 8
to 10 days after which bactericidal activity fell to less than 1.0
log10 cfu/ml. Sera kept at 37uC were assessed six- to twelve-
hourly for bactericidal activity against D23580. At this tempera-
ture, bactericidal activity fell more rapidly than at 22uC and was
less than 1.0 log10 cfu/ml after 54 hours for two sera and after 72
hours for the other two sera.
Delayed Separation of Serum from Clotted Human Blood
does not Reduce Ability to Kill Salmonella
Delayed separation of serum from blood often occurs due to
delays in transportation of blood samples from clinic to laboratory.
To investigate the effect of up to four days delay in separation of
serum from blood on Salmonella killing, we performed the serum
bactericidal assay using blood kept at either 4uC (Fig. 4A, C, E, G)
or 22uC (Fig. 4B, D, F, H) post-venesection. Blood was separated
either on the day of venesection or after one to four days, and,
following separation, sera were stored at 4uC. Assays were
performed on all samples a total of four days post-venesection.
Compared with fresh sera, there was no significant difference in
the bactericidal activity of the serum after 1, 2, 3 or 4 days’ delay
in separation from whole blood at any of the three assay time
points (45, 90 and 180 minutes), regardless of whether the blood
had been stored at 4uC (ANOVA, p=0.09 to 0.74) or 22uC
(p=0.19 to 0.99).
Loss of complement activity following four days of delayed
separation of serum from blood could occur to a degree that would
Figure 4. Effect of delayed separation of serum from clotted human blood on ability to kill S. Typhimurium D23580. Blood from four
healthy adults (subjects 1–4 corresponding with panels A.–B., C.–D., E.–F. and G.–H. respectively) was kept at 4uC (A., C., E., G.) or 22uC (B., D., F., H.)
post-venesection and serum separated the same day (red circles) or after one (green squares), two (blue triangles), three (purple diamonds ), or four
(orange inverted triangles) days after venesection. Separated sera were then maintained at 4uC without freezing for a total of four days post
venesection before being used in the serum bactericidal assays and compared with fresh serum from each donor (black circles). Changes in cfu/ml are
plotted against the duration of assay.
doi:10.1371/journal.pone.0049147.g004
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Figure 5. Effect of delayed separation of serum from clotted human blood on classical and alternative pathway hemolytic
complement activity. Classical (A., C., E., G.) and alternative (B., D., F., H.) pathway hemolytic complement activity in sera from four subjects
(corresponding with panels A–B, C–D, E–F, G–H) separated from clotted blood on the day of venesected (day 0) or stored at 4uC (red circles) or 22uC
(green squares) and separated 1–4 days post-venesection. Once separated, all samples were maintained at 280uC until tested in the radial
immunodiffusion assays.
doi:10.1371/journal.pone.0049147.g005
Complement Activity Stability against Salmonella
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not be detectable by our Salmonella killing assay. To test this, we
took further samples of blood from the four donors and separated
and froze serum on the day of venesection, and after 1, 2, 3 or 4
days at 4uC and 22uC for functional complement pathway assays.
There was no significant difference in classical or alternative
pathway hemolytic complement activity with serum that had been
separated from blood after four days at 4uC or 22uC, compared
with serum separated and frozen on the day of venesection (Fig. 5).
Blocking of Alternative Pathway Activity with Anti-
properdin Antibodies Inhibits Serum Killing of Salmonella
In order to test whether killing of S. Typhimurium D23580 was
dependent on the alternative pathway of complement, we
performed the serum bactericidal assay with anti-properdin
antibodies added to fresh serum from subject 1 at a final
concentration of 0.92 mg/ml in order to block the alternative
pathway. Killing of Salmonella was fully inhibited with net bacterial
growth at all time points in the assay (Fig. 6).
Discussion
Despite the importance given to careful handling of serum in
order to preserve complement activity, the available scientific
literature describing experimental studies on this activity dates
from the first half of the 20th century. Much of the data described
in this literature relates to studies of animal, rather than human
complement, and uses hemolytic complement assays that may not
reflect the bactericidal assay against Salmonella or bacteria in
general, which usually depend on the combined action of antibody
and complement.
A common assumption is that frozen aliquots of serum should
be used on the day of thawing when required for bactericidal
assays. Our findings indicate that this is not the case, since thawed
serum stored at 4uC effects normal levels of killing of Salmonella for
35 days. For three of the four sera, killing was still obtained after
70 days at 4uC. We have previously shown that classical pathway
of complement is required for bactericidal activity against invasive
African isolates of Salmonella [3]. These current findings are
consistent with only a small level of classical pathway activity being
required for this activity, a level that can be undetectable by
hemolytic radial immunodiffusion assay. Another assumption is
that serum must be separated from blood immediately after
clotting and stored at 280uC until use in order to retain
complement function. We found no loss of ability to kill Salmonella
in our serum bactericidal assay using blood that had been left for
four days at room temperature prior to serum separation and use.
It is possible that some loss of complement activity, undetectable
by our serum bactericidal assay, which standardly uses undiluted
serum, may have occurred during this time. However, the lack of
change in functional complement activity assessed by the
hemolytic assays indicates that this was not the case.
Mechanistically, these data are compatible with the hypothesis
that once the classical pathway has initiated C3b deposition on
Salmonella, this is sufficient for the deployment of the alternative
pathway which then becomes the critical determinant of
bactericidal activity. When we performed the bactericidal assay
with anti-properdin antibodies to block the alternative pathway,
killing was fully inhibited confirming the critical role of alternative
pathway in serum killing of Salmonella. It is surprising that serum
from subject 1 had only half the duration of bactericidal activity of
the other three sera when stored at 4uC. Our data do not provide
an explanation for this, since longevity of classical and alternative
pathway hemolytic complement activity for this serum was no less
than that for the other three sera, and there was no evidence for
the blocking activity which we have previously described in serum
from some HIV-infected African adults [11]. The difference in
longevity of bactericidal activity between this serum and the others
was less apparent at 22uC and 37uC.
Perhaps the most surprising finding of the study was the lack of
any discernible effect on bactericidal activity of up to three freeze-
thaw cycles, given the accepted view that freeze-thaw cycles are to
be avoided in the context of preservation of complement function
[8]. Consistent with this finding, a report from 1927 found that
guinea pig serum could be subjected to twelve freeze-thaw cycles
without an appreciable decrease of hemolytic activity [12]. As has
previously been described using hemolytic assays [5,6], we found
that the longevity of bactericidal activity of human serum against
Salmonella was reduced with increased storage temperature post-
thawing. The practical implication of this is that if thawed human
serum is to be used over an extended number of days, it is
important that it is kept refrigerated.
When considering the significance of the findings of the current
study, it is important to consider that much of the non-variable
blood and serum handling involved was conducted under optimal
conditions. Different findings could be expected if, for example,
frozen serum had been stored at temperatures higher than280uC,
or if during freeze-thaw cycles, serum had been left thawed for
extended periods of time before refreezing. We have allowed blood
to clot at both room temperature and 4uC, as described in the
present study, and have found no difference in integrity of
complement activity with either protocol. Blood clots more rapidly
at room temperature and should be separated and frozen sooner
than blood stored at 4uC. As expected, diluted serum loses
bactericidal activity more rapidly than undiluted serum, so serum
to be used for serum bactericidal assays and other functional
complement assays should be stored undiluted. It is important to
remember that human complement does not necessarily behave
the same as animal complement in bactericidal assays [9].
Nevertheless, the findings of the study indicate that the current
guidelines concerning manipulation and storage of serum to
Figure 6. Effect of presence of Factor B antibody on ability of
human serum to kill S. Typhimurium D23580. Killing of bacteria
by 90% fresh serum from subject 1 and 10% polyclonal anti-Factor B
antibody (final concentration 0.92 mg/ml) (red circles), compared with
90% fresh serum from subject 1 and 10% PBS (green squares) and 100%
heat-inactivated serum (black triangles) at 45, 90 and 180 minutes in the
serum bactericidal assay using 106 cfu/ml S. Typhimurium D23580.
doi:10.1371/journal.pone.0049147.g006
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preserve complement integrity and function leave a large margin
for safety.
It possible that serum from some individuals may perform less
well that than that of others due, for example, to polymorphisms of
the alleles encoding C4. Furthermore, serum from individuals with
complement-consuming conditions such as autoimmunity or
hepatitis C infection would be unsuitable for use. The current
study only tested serum from four individuals which was due to the
large number of assays required to determine the conditions for
serum manipulation. Ideally, serum for each new donor should be
tested in an established assay system prior to using it routinely.
Serum bactericidal assays, particularly against meningococcus,
often use animal complement as a source of exogenous comple-
ment usually in the form of baby rabbit serum. While this can
facilitate standardization, it has led to problems with assay
sensitivity and specificity leading some to propose the use of
human complement instead [13]. The current study supports the
use of human serum as a source of complement for bactericidal
assays by demonstrating the robust characteristics of human
complement. Moreover, in serum bactericidal assays such as the
one described to examine killing of Salmonella, the subject’s own
endogenous complement is used allowing assessment of the
combined activity of the subject’s antibody and complement in
the bactericidal process. This could provide a more accurate
indication of the complement-mediated bactericidal activity that
each individual has against a pathogen.
While the current study was focused primarily on the
preservation of complement activity in relation to bactericidal
activity of human serum against Salmonella, it is important to
establish the conditions for serum handling to each particular in
vitro assay system and complement source. This study provides
a model for the testing of conditions of serum manipulation that
can be applied to other assay systems and other sources of
complement.
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